Skip to main
  1. Stocks
  2. Novocure
  3. Forecast
NVCR

Novocure (NVCR) Stock Forecast & Price Target

Novocure (NVCR) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 17%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

NovoCure is showing a strong fundamental setup because 2Q26 revenue rose 16% year over year to $183.6 million, with growth across all three commercial products, gross margin expanding to 78%, and total active patients reaching 5,128 globally. The company’s outlook is supported by accelerating adoption in the core GBM franchise, an encouraging Optune Pax launch with 418 prescriptions and 285 active patients in 2Q26, and especially the rapid uptake of Optune Lua in Japan, where active patients rose from 6 in 1Q26 to 64 and revenue reached $1.8 million. Management also improved 2026 revenue guidance to $710 million to $725 million and adjusted EBITDA guidance to $0 million to $15 million while cutting R&D spending by about $90 million, signaling that commercial momentum is improving even as the pipeline advances toward additional regulatory and clinical catalysts.

Bears say

NovoCure is facing a negative outlook because the FDA’s Not Approvable Letter for Optune Mya in NSCLC brain metastases signals meaningful regulatory risk and weakens confidence in the company’s ability to expand its TTFields franchise. The cited uncertain clinical benefit, along with management’s need to determine whether approval is possible without additional studies, increases execution risk and undermines visibility into future commercialization. Beyond this setback, the thesis still depends on Pax and Lua proving they can drive durable growth beyond Gio, while the limited commercial opportunity in brain metastases and uncertainty around treatment duration constrain upside.

Novocure (NVCR) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 17% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.

Novocure (NVCR) Analyst Forecast & Price Prediction

Get the latest Novocure (NVCR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Novocure (NVCR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novocure (NVCR) Forecast

Analysts have given Novocure (NVCR) a Buy based on their latest research and market trends.

According to 6 analysts, Novocure (NVCR) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novocure (NVCR)


Novocure (NVCR) Analyst Forecast & Price Prediction

Get the latest Novocure (NVCR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Novocure (NVCR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover NVCR stock data and trends